In 2023, Estonia had the highest incidence of drug-induced deaths in Europe at *** per million population. This was followed by Latvia at *** deaths per million population, and ** deaths per million in Norway. On the other hand, in Romania, there were only * drug-induced deaths per million population in 2023. Number of drug-induced deaths There were nearly *** thousand drug-related deaths reported in the EU in 2022. There was a steady increase in the number of deaths in the EU from only *** thousand cases in 2013. When combined with Turkey and Norway, the number of drug-induced deaths in 2022 nearly reached ***** thousand. This was the highest number of drug-related deaths recorded in the given period. Drug deaths by gender and age In 2022, 77 percent of drug-induced deaths reported in the EU were attributed to men. Half of the deaths that occurred among men were among those aged between 25 and 44 years. Similarly, the largest share of female deaths due to drug use was also reported in the same age group.

Deaths as a result of drug overdoses in Portugal amounted to ** in 2019, which is the second highest number of annual deaths reported in the provided time interval. In 2011, drug deaths fell to only **, before reaching ** just four years later. In 2020, drug-induced deaths were counted at **. In 2021, there were ** deaths by overdose, the highest value recorded. Low death rate compared to Europe When compared with the rest of Europe, Portugal has a fairly low incidence of drug deaths. A rate of ** drug deaths per million population (pmp) means that Portugal only had a higher drug death rate than a few countries in the continent, and a significantly lower rate than the ** deaths pmp in Norway, which is the highest in Europe. In 2001, Portugal became the first country in the world to decriminalize the consumption of drugs. The low amount of drug deaths in Portugal is usually attributed to this policy of decriminalization. Breakdown of drugs consumed The class of drugs that caused the highest share of individuals seeking treatment in Portugal, in 2021, were cannabis, with approximately ** percent of Portuguese drug treatment entrants seeking treatment primarily due to the use of this drug class. With a slightly lower share, opioids caused **** percent of drug treatment entries in Portugal. In 2022, Portugal had approximately ****** individuals in opioid substitution treatment, which was the sixth-highest in Europe.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2F8a1e63df085793d18e2d1fa2109ebd44%2Fgrap%20video%201.gif?generation=1708634385396138&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2F296225796c579724b56cb1d746475d93%2FToday%20(1).gif?generation=1708634392024756&alt=media" alt="">

Annual number of deaths in the United States from drug overdose per 100,000 people. Overdoses can result from intentional excessive use of a substance, but can also result from 'poisoning' where substances have been altered or mixed, such that the user is unaware of the drug's potency.

The data of this indicator is based on the following sources: US Centers for Disease Control and Prevention WONDER Data published by US Centers for Disease Control and Prevention WONDER

Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates How we process data at Our World in Data: All data and visualizations on Our World in Data rely on data sourced from one or several original data providers. Preparing this original data involves several processing steps. Depending on the data, this can include standardizing country names and world region definitions, converting units, calculating derived indicators such as per capita measures, as well as adding or adapting metadata such as the name or the description given to an indicator.

At the link below you can find a detailed description of the structure of our data pipeline, including links to all the code used to prepare data across Our World in Data.

Read about our data pipeline How to cite this data: In-line citation If you have limited space (e.g. in data visualizations), you can use this abbreviated in-line citation:

Any opioids Deaths per 100,000 people attributed to any opioids.

Source US Centers for Disease Control and Prevention WONDER – processed by Our World in Data Unit deaths per 100,000

As of 2024, 14.5 percent of the adult population in Spain was estimated to have used illicit drugs in the previous year, with this being the highest estimated figure in any European country. The Netherlands had the second-highest rate of illicit drug use, at around 13.7 percent. Examples of problem drug use in Europe According to the latest figures, the Netherlands and France had the highest share of their population who had used cocaine in the previous year in Europe. Around 2.7 percent of the Dutch and French population had used cocaine in the preceding twelve months, followed by Spain and Ireland, which both had over two percent of individuals using cocaine. When it comes to amphetamines, Finland had the highest prevalence of use, with 2.3 percent of their respective populations using in the last year. Drug deaths in Europe In 2021, 54 percent of men who died as a result of drug use in Europe were aged between 25 and 44 years, while 39 percent of drug deaths among women were also in this age group. Estonia was the country in Europe with the highest incidence of drug deaths, at 135 per million population.

West Virginia is currently the state with the highest drug overdose death rate in the United States, with 82 deaths per 100,000 population in 2023. Although West Virginia had the highest drug overdose death rate at that time, California was the state where the most people died from drug overdose. In 2023, around ****** people in California died from a drug overdose. The main perpetrator Opioids account for the majority of all drug overdose deaths in the United States. Opioids include illegal drugs such as heroin, legal prescription drugs like oxycodone, and illicitly manufactured synthetic drugs like fentanyl. The abuse of opioids has increased in recent years, leading to an increased number of drug overdose deaths. The death rate from heroin overdose hit an all-time high of *** per 100,000 population in 2016 and 2017, but has decreased in recent years. Now, illicitly manufactured synthetic opioids such as fentanyl account for the majority of opioid overdose deaths in the United States. Opioid epidemic The sharp rise in overdose deaths from opioids has led many to declare the United States is currently experiencing an opioid epidemic or opioid crisis. The causes of this epidemic are complicated but involve a combination of a rise in dispensed prescriptions, irresponsible marketing from pharmaceutical companies, a lack of physician-patient communication, increased social acceptance of prescription drugs, and an increased supply of cheap and potent heroin on the streets.

The following dataset is the World Drug Report 2021 produced by the United Nations Office on Drugs and Crime. https://www.unodc.org/unodc/en/data-and-analysis/wdr2021_annex.html

The Executive Summary: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf

Special points of interest from the report: - Cannabis has come to be seen as less risky by adolescents from 1995 to 2019, but the herb potency has increased 4x in that time period. - Web-based sales have increased dramatically. - Number of drug users in Africa is projected to rise by 40 per cent by 2030, based on expected population growth in the 15-64 demographic. - Drug markets quickly recovered after the onset of the pandemic, but some trafficking dynamics have been accelerated during Covid-19 - Non-medical use of cannabis and sedatives has increased globally during the pandemic

On Opioids specifically: - The two pharmaceutical opioids most commonly used to treat people with opioid use disorders, methadone and buprenorphine, have become increasingly accessible over the past two decades. The amount available for medical use has increased sixfold since 1999, from 557 million daily doses in that year to 3,317 million by 2019. - The amounts of fentanyl and its analogues seized globally have risen rapidly in recent years, and by more than 60 per cent in 2019 compared with a year earlier. Overall, these amounts have risen more than twenty-fold since 2015. The largest quantities were seized in North America. - Elsewhere in the world, other pharmaceutical opioids (codeine and tramadol) predominate. Over the period 2015–2019, the largest quantities of tramadol seized were reported in West and Central Africa; they accounted for 86 per cent of the global total. Codeine was intercepted in large quantities in Asia, often in the form of diverted cough syrups. - Almost 50,000 people died from overdose deaths attributed to opioids in the United States in 2019, more than double the 2010 figure. By comparison, in the European Union, the figure for all drug-related overdoses (mostly relating to opioid use) stood at 8,300 in 2018, despite the larger population. - However, the opioid crisis in North America is evolving. The number of deaths attributed to heroin and the non-medical use of pharmaceutical opioids such as oxycodone or hydrocodone has been declining over the past five years. - The crisis is now driven mainly by overdose deaths attributed to synthetic opioids such as fentanyl and its analogues. Among the reasons for the large number of overdose deaths attributed to fentanyls is that the lethal doses of them are often small when compared with other opioids. Fentanyl is up to 100 times more potent than morphine. - The impact of fentanyl is illustrated even further by the fact that more than half of the deaths attributed to heroin also involve fentanyls. Synthetic opioids also contribute significantly to the increased number of overdose deaths attributed to cocaine and other psychostimulants, such as methamphetamine.

This statistic displays the total number of drug deaths in the Netherlands in 2022, by type. In that year, there were *** drug-related deaths in the Netherlands. Over half of these deaths were caused by opioids. Cocaine was responsible for another ** deaths. Rising drug-induced deaths across Europe From 2010 to 2023, the annual number of drug deaths in the Netherlands increased by over three times, rising from ** to *** deaths per year. The Netherlands is not alone in grappling with drug-related deaths. Across the European Union, there has been a notable increase in drug-induced fatalities over the past decade. In 2022, nearly *** thousand people died from illicit drug overdoses in EU countries, with this number rising to almost ***** thousand when including Norway and Turkey. Demographics and risk factors The majority of drug-induced deaths in Europe occur among individuals aged 25 to 44 years, with men being disproportionately affected. In 2023, ** percent of male drug deaths and ** percent of female drug deaths fell within this age group. Notably, opioids play a significant role in drug-related fatalities across Europe, with countries like Denmark, Austria, and Latvia reporting that over ** percent of their drug-related deaths involved opioids.

In 2023, around 72,776 people in the United States died from a drug overdose that involved fentanyl. This was the second-highest number of fentanyl overdose deaths ever recorded in the United States, and a significant increase from the number of deaths reported in 2019. Fentanyl overdoses are now the driving force behind the opioid epidemic, accounting for the majority of overdose deaths in the United States. What is fentanyl? Fentanyl is an extremely potent synthetic opioid similar to morphine, but more powerful. It is a prescription drug but is also manufactured illegally and is sometimes mixed with other illicit drugs such as heroin and cocaine, often without the user’s knowledge. The potency of fentanyl makes it very addictive and puts users at a high risk for overdose. Illegally manufactured fentanyl has become more prevalent in the United States in recent years, leading to a huge increase in drug overdose deaths. In 2022, the rate of drug overdose death involving fentanyl was 22.7 per 100,000 population, compared to a rate of just one per 100,000 population in the year 2013. Fentanyl overdoses by gender and race/ethnicity As of 2022, the rate of drug overdose deaths involving fentanyl in the United States is over two times higher among men than women. Rates of overdose death involving fentanyl were low for both men and women until around the year 2014 when they began to quickly increase, especially for men. In 2022, there were around 19,880 drug overdose deaths among women that involved fentanyl compared to 53,958 such deaths among men. At that time, the rate of fentanyl overdose deaths was highest among non-Hispanic American Indian or Alaska Natives and lowest among non-Hispanic Asians. However, from the years 2014 to 2018, non-Hispanic whites had the highest fentanyl overdose death rates.

To: State, territorial, tribal, and local policymakers and administrators of agencies and programs focused on child, youth, and family health and well-being Dear Colleagues, Thank you for your work to support children, youth, and families. Populations served by Administration for Children and Families (ACF)-funded programs — including victims of trafficking or violence, those who are unhoused, and young people and families involved in the child welfare system — are often at particularly high risk for substance use and overdose. A variety of efforts are underway at the federal, state, and local levels to reduce overdose deaths. These efforts focus on stopping drugs from entering communities, providing life-saving resources, and preventing drug use before it starts. Initiatives across the country are already saving lives: the overdose death rate has declined over the past year but remains too high at 32.6 per 100,000 individuals. Fentanyl, a powerful synthetic opioid, raises the risk of overdose deaths because even a tiny amount can be deadly. Young people are particularly at risk for fentanyl exposure, driven in part by widespread availability of counterfeit pills containing fentanyl that are marketed to youth through social media. While overdose deaths among teens have recently begun to decline, there were 6,696 deaths among adolescents and young adults in 2022 (the latest year with data available)[1], making unintentional drug overdose the second leading cause of death for youth ages 15—19 and the first leading cause of death among young adults ages 20-24.[2] Often these deaths happen with others nearby and can be prevented when opioid overdose reversal medications, like naloxone, are administered in time. CDC’s State Unintentional Drug Overdose Reporting System dashboard shows that in all 30 jurisdictions with available data, 64.7% of drug overdose deaths had at least one potential opportunity for intervention.[3] Naloxone rapidly reverses an overdose and should be given to any person who shows signs of an opioid overdose or when an overdose is suspected. It can be given as a nasal spray. Studies show that naloxone administration reduces death rates and does not cause harm if used on a person who is not overdosing on opioids. States have different policies and regulations regarding naloxone distribution and administration. Forty-nine states and the District of Columbia have Good Samaritan laws protecting bystanders who aid at the scene of an overdose.[4] ACF grant recipients and partners can play a critical role in reducing overdose deaths by taking the following actions: Stop Overdose Now (U.S. Centers for Disease Control and Prevention) Integrating Harm Reduction Strategies into Services and Supports for Young Adults Experiencing Homelessness (PDF) (ACF) Thank you for your dedication and partnership. If you have any questions, please contact your local public health department or state behavioral health agency. Together, we can meaningfully reduce overdose deaths in every community. /s/ Meg Sullivan Principal Deputy Assistant Secretary [1] Products - Data Briefs - Number 491 - March 2024 [2] WISQARS Leading Causes of Death Visualization Tool [3] SUDORS Dashboard: Fatal Drug Overdose Data | Overdose Prevention | CDC [4] Based on 2024 report from the Legislative Analysis and Public Policy Association (PDF). Note that the state of Kansas adopted protections as well following the publication of this report. Metadata-only record linking to the original dataset. Open original dataset below.

Postmortem Toxicology Testing Market Outlook

The global postmortem toxicology testing market size is projected to grow from $1.2 billion in 2023 to $2.3 billion by 2032, exhibiting a CAGR of 7.2% during the forecast period. This growth is driven by increasing incidences of drug-related deaths and advancements in toxicology testing technologies. The rising awareness about the importance of forensic science in solving criminal cases and determining causes of death further propels the market.

The key growth factor for the postmortem toxicology testing market is the increasing prevalence of drug-related fatalities worldwide. The opioid crisis, particularly in North America, has escalated the demand for comprehensive toxicology testing procedures. Drugs like fentanyl and heroin are often involved in overdose cases, necessitating detailed toxicological analyses to determine the exact cause of death. Additionally, the rise in prescription drug abuse has heightened the need for accurate and timely toxicology testing.

Innovative advancements in toxicology testing technologies are also driving market growth. The development of highly sensitive and specific instruments, such as advanced chromatography and mass spectrometry systems, allows for the detection of minute quantities of toxic substances. These advancements ensure that even trace amounts of drugs or poisons can be detected, providing critical information in forensic investigations and contributing to the overall reliability and accuracy of postmortem examinations.

Growing investments in forensic science infrastructure, especially in developing regions, are another significant factor propelling market expansion. Governments and private organizations are increasingly allocating funds to upgrade forensic laboratories and acquire state-of-the-art toxicology testing equipment. This trend is particularly evident in countries with high crime rates and drug abuse problems, where enhanced forensic capabilities are essential for effective law enforcement and judicial processes.

Regionally, North America dominates the postmortem toxicology testing market due to the high incidence of drug-related deaths and substantial investments in forensic science. Europe follows closely, driven by stringent regulations and a strong focus on forensic research and development. The Asia Pacific region is expected to witness the fastest growth, attributed to increasing government initiatives to strengthen forensic infrastructure and rising awareness about the importance of toxicology testing in criminal investigations.

Product Type Analysis

Instruments constitute a crucial segment of the postmortem toxicology testing market. This segment includes a variety of sophisticated equipment such as chromatography systems, mass spectrometers, and immunoassay analyzers, which are vital for precise toxicological analysis. The demand for advanced instruments has surged as they offer high sensitivity and specificity, essential for detecting low concentrations of toxic substances in biological specimens. Manufacturers are continuously innovating to enhance the accuracy and efficiency of these instruments, thereby driving market growth.

Reagents are another significant component of the market, encompassing a wide range of chemicals and solutions used in toxicology tests. The growing complexity of toxicological analyses necessitates the use of high-quality reagents to ensure reliable results. The increasing number of drug overdose cases and poisoning incidents has spurred the demand for diverse reagents capable of detecting various toxicants. Additionally, the development of novel reagents tailored to specific toxicological needs further augments this segment’s growth.

Consumables, including test kits, sample collection devices, and disposable tools, form an essential part of the postmortem toxicology testing market. The recurring need for these items in every testing procedure ensures a steady demand. The expansion of forensic laboratories and the rising number of toxicology tests conducted globally contribute to the growth of this segment. Moreover, the emphasis on maintaining high standards of hygiene and accuracy in toxicological analyses drives the continuous procurement of consumables.

The integration of advanced technologies into instruments and reagents has revolutionized toxicology testing. For instance, the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) has significantly enhanced the detection capabilities of toxicological instruments. Similarly, t

The Mortality Detail File: External Cause Extract is a special subset of data prepared from the MORTALITY DETAIL FILES, 1968-1991 (ICPSR 7632). Due to changes in Cause of Death definitions incorporated in the INTERNATIONAL CLASSIFICATION OF DISEASES, NINTH REVISION (ICD-9), the 1968-1978 data files differ slightly from the 1979-1980 data files. The 1968-1978 data reflect cause of death codes of the INTERNATIONAL CLASSIFICATION OF DISEASES ADAPTED FOR USE IN THE UNITED STATES, EIGHTH REVISION (ICDA-8). The period immediately following (1979-80) utilizes ICD-9 cause of death codes. In addition to the differences in the Cause of Death codes and recodes, the 1979-1980 data include three variables not available in the 1968-1978 datasets. These are: mortality by marital status, state or country of birth, and place of death and status of decedent when death occurred in a hospital or medical center. With these exceptions, the data are similar in structure and content to the 1968-1978 data and provide detailed personal and geographic information such as month and day of death, decedent's race and gender, age of deceased at time of death, place of decedent's residence (specific to the city level), place of death (specific to the county level), and whether an autopsy was performed. The 1979-1980 files also contain new variables pertinent to criminal justice research: handgun versus other gun accidents, handgun versus other firearm suicides, handgun versus other firearm homicides, and drug poison versus other poison homicides.

Maintaining healthcare for noncommunicable diseases (NCDs) is particularly important during the COVID-19 pandemic; however, diversion of resources to acute care, and physical distancing restrictions markedly affected management of NCDs. We aimed to assess the medication management practices in place for NCDs during the second wave of the COVID-19 pandemic across European countries. In December 2020, the European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE) conducted a cross-sectional, web-based survey in 38 European and one non-European countries. Besides descriptive statistics of responses, nonparametric tests and generalized linear models were used to evaluate the impact on available NCD services of the number of COVID-19 cases and deaths per 100,000 inhabitants, and gross domestic product (GDP) per capita. Fifty-three collaborators from 39 countries completed the survey. In 35 (90%) countries face-to-face primary-care, and out-patient consultations were reduced during the COVID-19 pandemic. The mean ± SD number of available forms of teleconsultation services in the public healthcare system was 3 ± 1.3. Electronic prescriptions were available in 36 (92%) countries. Online ordering and home delivery of prescription medication (avoiding pharmacy visits) were available in 18 (46%) and 26 (67%) countries, respectively. In 20 (51%) countries our respondents were unaware of any national guidelines regarding maintaining medication availability for NCDs, nor advice for patients on how to ensure access to medication and adherence during the pandemic. Our results point to an urgent need for a paradigm shift in NCD-related healthcare services to assure the maintenance of chronic pharmacological treatments during COVID-19 outbreaks, as well as possible future disasters.

Measuring homicides across the world helps us understand violent crime and how people are affected by interpersonal violence.

But measuring homicides is challenging. Even homicide researchers do not always agree on whether the specific cause of death should be considered a homicide. Even when they agree on what counts as a homicide, it is difficult to count all of them.

In many countries, national civil registries do not certify most deaths or their cause. Besides lacking funds and personnel, a body has to be found to determine whether a death has happened. Authorities may also struggle to distinguish a homicide from a similar cause of death, such as an accident.

Law enforcement and criminal justice agencies collect more data on whether a death was unlawful — but their definition of unlawfulness may differ across countries and time.

Estimating homicides where neither of these sources is available or good enough is difficult. Estimates rely on inferences from similar countries and contextual factors that are based on strong assumptions. So how do researchers address these challenges and measure homicides?

In our work on homicides, we provide data from five main sources:

The WHO Mortality Database (WHO-MD)1 The Global Study on Homicide by the UN Office on Drugs and Crime (UNODC)2 The History of Homicide Database by Manuel Eisner (20033 and 20144) The Global Burden of Disease (GBD) study by the Institute for Health Metrics and Evaluation (IHME)5 The WHO Global Health Estimates (WHO-GHE)6 These sources all report homicides, cover many countries and years, and are frequently used by researchers and policymakers. They are not entirely separate, as they partially build upon each other.

The global handheld drugs of abuse analyzer market is experiencing robust growth, driven by increasing concerns regarding substance abuse and the need for rapid, on-site drug testing. This market, estimated at $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033. This significant expansion is fueled by several key factors. The rising prevalence of drug abuse globally, coupled with stringent law enforcement regulations and increased demand for point-of-care testing in addiction treatment centers and medical institutions, are major contributors to market growth. Technological advancements leading to more portable, user-friendly, and accurate devices further accelerate market adoption. The segment encompassing law enforcement agencies and customs currently holds the largest market share, reflecting the critical role of rapid drug identification in crime prevention and border security. However, the healthcare sector is a fast-growing segment, driven by the rising need for efficient and accurate drug screening in clinical settings. Different analytical methods, such as hair analysis, saliva analysis, and urinalysis, cater to diverse testing requirements, contributing to the market's diversification. While the high initial investment cost of the analyzers presents a restraint, the long-term cost savings associated with quick results and reduced reliance on centralized laboratories are expected to offset this barrier. The competitive landscape is characterized by a mix of established players like Thermo Fisher, Smiths Detection, and Bruker, alongside emerging companies. These companies are actively engaged in research and development, striving to enhance device sensitivity, portability, and the range of detectable substances. Geographic distribution shows strong market presence in North America and Europe, attributable to advanced healthcare infrastructure and stringent regulatory frameworks. However, rapidly developing economies in Asia Pacific are witnessing increasing demand, presenting lucrative growth opportunities. The continued focus on combating drug abuse, coupled with technological improvements and expanding applications, suggests the handheld drugs of abuse analyzer market will maintain its strong growth trajectory in the coming years. The market's evolution will be influenced by factors such as regulatory changes, technological innovation (e.g., incorporating AI and machine learning), and the increasing integration of handheld devices into broader crime investigation and public health surveillance systems.

The statistic shows the number of drug-related crimes in G-20 countries. There were ******* drug-related crimes in Germany in 2007.

Context

This dataset exhibits accidental death associated with drug overdose in Connecticut from 2012 to 2018. A "Y" value under the different substance columns indicates that particular substance was detected. Data are derived from an investigation by the Office of the Chief Medical Examiner which includes the toxicity report, death certificate, as well as a scene investigation. The “Morphine (Not Heroin)” values are related to the differences between how Morphine and Heroin are metabolized and therefor detected in the toxicity results. Heroin metabolizes to 6-MAM which then metabolizes to morphine. 6-MAM is unique to heroin, and has a short half-life (as does heroin itself). Thus, in some heroin deaths, the toxicity results will not indicate whether the morphine is from heroin or prescription morphine. In these cases the Medical Examiner may be able to determine the cause based on the scene investigation (such as finding heroin needles). If they find prescription morphine at the scene it is certified as “Morphine (not heroin).” Therefor, the Cause of Death may indicate Morphine, but the Heroin or Morphine (Not Heroin) may not be indicated.

“Any Opioid” – If the Medical Examiner cannot conclude whether it’s RX Morphine or heroin based morphine in the toxicity results, that column may be checked

Content

5105 raws and 38 columns: - ID: the death Id (anonymous person). - Date: Date of death. - Age, Sex, Race, ResidenceCity, ResidenceCounty, ResidenceState: age, sex race, Residence City, country, and state of the dead person. - DeathCity, DeathCounty, Location, LocationifOther, DescriptionofInjury, InjuryPlace, InjuryCity, InjuryCounty, InjuryState, COD, OtherSignifican: Deat relatedinformation 'Heroin', 'Cocaine', 'Fentanyl', 'FentanylAnalogue', 'Oxycodone', 'Oxymorphone', 'Ethanol', 'Hydrocodone', 'Benzodiazepine', 'Methadone', - 'Amphet', 'Tramad', 'Morphine_NotHeroin', 'Hydromorphone', 'Other', 'OpiateNOS', 'AnyOpioid': Noacotics taken by paersons - MannerofDeath: Death manner suicide ('Accident', 'Pending', 'Natural')

BackgroundOpioid maintenance treatment (OMT) has the potential to reduce mortality rates substantially. We aimed to compare all-cause and overdose mortality among OMT patients while in or out of OMT in two different countries with different approaches to OMT.MethodsTwo nation-wide, registry-based cohorts were linked by using similar analytical strategies. These included 3,637 male and 1,580 female patients enrolled in OMT in Czechia (years 2000–2019), and 6,387 male and 2,078 female patients enrolled in OMT in Denmark (years 2007–2018). The direct standardization method using the European (EU-27 plus EFTA 2011–2030) Standard was employed to calculate age-standardized rate to weight for age. All-cause and overdose crude mortality rates (CMR) as number of deaths per 1,000 person years (PY) in and out of OMT were calculated for all patients. CMRs were stratified by sex and OMT medication modality (methadone, buprenorphine, and buprenorphine with naloxone).ResultsAge-standardized rate for OMT patients in Czechia and Denmark was 9.7/1,000 PY and 29.8/1,000 PY, respectively. In Czechia, the all-cause CMR was 4.3/1,000 PY in treatment and 10.8/1,000 PY out of treatment. The overdose CMR was 0.5/1,000 PY in treatment and 1.2/1,000 PY out of treatment. In Denmark, the all-cause CMR was 26.6/1,000 PY in treatment and 28.2/1,000 PY out of treatment and the overdose CMR was 7.3/1,000 PY in treatment and 7.0/1,000 PY out of treatment.ConclusionCountry-specific differences in mortality while in and out of OMT in Czechia and Denmark may be partly explained by different patient characteristics and treatment systems in the two countries. The findings contribute to the public health debate about OMT management and may be of interest to practitioners, policy and decision makers when balancing the safety and accessibility of OMT.

The global forensic toxicology testing market is booming, projected to reach $4.5 billion by 2033, driven by rising crime rates, technological advancements, and the increasing prevalence of substance abuse. Learn about market trends, key players, and regional growth in this comprehensive analysis.